Targets › WNT
3 programs from 3 companies in 3 trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: the race on WNT, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Katherine Garman | Pyrvinium Wnt pathway inhibitor | WNT | Phase 2 | Gastric Intestinal Metaplasia | – |
| Thomas Jefferson University | Pyrvinium Pamoate Wnt/β-catenin pathway inhibitor | WNT | Phase 1 | Resectable Pancreatic Ductal Adenocarcinoma | Dec 2026 |
| National Cancer Institute (NCI) | Cirtuvivint Wnt signaling pathway inhibitor | WNT | Phase 1 | Acute Myeloid Leukemia | Jun 2028 |
Acute Myeloid Leukemia (1) Gastric Intestinal Metaplasia (1) Resectable Pancreatic Ductal Adenocarcinoma (1)
small molecule (3)
National Cancer Institute (NCI) (1) Katherine Garman (1) Thomas Jefferson University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.